Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
